Kidney outcomes and safety of sodium-glucose cotransporter-2 inhibitor therapy in autosomal dominant polycystic kidney disease: systematic review and meta-analysis.
Mehmet Kanbay, Berk Mizrak, Erdem Cig et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the efficacy and safety of sodium-glucose cotransporter-2 (SGLT2) inhibitors in 451 patients with autosomal dominant polycystic kidney disease (ADPKD). The study found a significant reduction in the rate of eGFR decline during the first year with SGLT2 inhibitors, showing a mean difference of 0.65 mL/min/1.73 m² per year compared to placebo.
Key findings
- SGLT2 inhibitor therapy significantly reduced the rate of eGFR decline by 0.65 mL/min/1.73 m² per year compared to placebo.
- No significant difference in eGFR slope change was observed between SGLT2 and non-SGLT2 inhibitor therapies.
- SGLT2 inhibitors did not show a statistically significant effect on total kidney volume change.
Why it matters
Understanding the effects of SGLT2 inhibitors on kidney outcomes in ADPKD is crucial, as these patients are often excluded from major clinical trials. This research provides insights into potential therapeutic options for managing kidney function in this population.
What to keep in mind
The evidence is limited by small sample sizes, predominantly observational designs, and substantial clinical and methodological heterogeneity.